丙型肝炎3型疾病
Hepatitis C genotype 3 disease.
作者信息
Kattakuzhy Sarah, Levy Rachel, Rosenthal Elana, Tang Lydia, Wilson Eleanor, Kottilil Shyam
机构信息
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, 5415 W, Cedar Lane Suite 203b, Bethesda, MD, 20814, USA.
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
出版信息
Hepatol Int. 2016 Nov;10(6):861-870. doi: 10.1007/s12072-016-9748-z. Epub 2016 Jun 21.
Hepatitis C genotype 3 (GT-3) infection comprises up to 30 % of all HCV infections worldwide, with roughly 54.3 million cases concentrated in South and Southeast Asia. Longitudinal studies have demonstrated significantly increased rates of steatosis, fibrosis, and hepatocellular carcinoma in GT-3 disease, thus distinguishing this genotype as both the most difficult and urgent to treat. However, novel direct-acting antiviral agents currently approved have not demonstrated the uniform potency seen in GT-1 disease for GT-3. This review outlines (1) the epidemiology and natural history, (2) phase II and III clinical trials demonstrating effective treatment options, and (3) current and future therapeutic issues in the quest to eradicate hepatitis C genotype 3 disease.
丙型肝炎基因3型（GT-3）感染占全球所有丙肝病毒感染病例的30%，约5430万病例集中在南亚和东南亚地区。纵向研究表明，GT-3型疾病的脂肪变性、纤维化和肝细胞癌发病率显著增加，因此该基因型被认为是最难治疗且最急需治疗的。然而，目前获批的新型直接抗病毒药物在GT-3型疾病中并未表现出在GT-1型疾病中所见的同等效力。本综述概述了：（1）流行病学和自然史；（2）证明有效治疗方案的II期和III期临床试验；（3）在根除丙型肝炎基因3型疾病过程中当前和未来的治疗问题。
Zotero 插件